Patents Issued in March 19, 2019
-
Patent number: 10231950Abstract: The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.Type: GrantFiled: October 2, 2015Date of Patent: March 19, 2019Assignee: Convergence Pharmaceuticals LimitedInventor: Valerie Morisset
-
Patent number: 10231951Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.Type: GrantFiled: March 2, 2016Date of Patent: March 19, 2019Assignee: SANIONA A/SInventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
-
Patent number: 10231952Abstract: Described herein are methods of decreasing the proliferation of prostate cancer cells in a mammalian subject by administering to a subject in need thereof a composition comprising an AVPR antagonist in amount effective to decrease proliferation of the cancer cells. Also provided are methods of inducing prostate cancer cell death (or decreasing invasion migration of the prostate cancer cells) in a mammalian subject by administering to a subject in need thereof a composition comprising an AVPR antagonist.Type: GrantFiled: July 28, 2015Date of Patent: March 19, 2019Assignee: UNIVERSITY OF MIAMIInventor: Kerry L. Burnstein
-
Patent number: 10231953Abstract: The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.Type: GrantFiled: December 16, 2015Date of Patent: March 19, 2019Assignee: Zenith Epigenetics Ltd.Inventors: Olesya Kharenko, Peter Ronald Young, Samuel David Brown, Bryan Cordell Duffy, Shuang Liu, Peter Guzzo
-
Patent number: 10231954Abstract: The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R?? but may not be a quaternary C atom; R? is —OR1, —CONH2, —CF3, F, —OH, —NO2, —CN or —OCOR1 in which R1, is C1-3 alkyl and each may be in the beta or gamma position; R? is C1-3 alkyl or H; and R?? is H or a group consisting of 1-12 non-hydrogen atoms and may be linear, branched and/or incorporate one or more cyclic groups, cyclic groups may be aromatic and/or heterocyclic and 2 or more cyclic groups may be linked or fused and each may be substituted; or a salt, hydrate or solvate of a compound of formula (I) for use in the treatment or prevention of a neurodegenerative disorder by inhibiting formation of neurofibrillary (tau) tangles and/or by inhibiting Dyrk 1A. The invention further relates to non-therapeutic uses of these compounds.Type: GrantFiled: February 4, 2015Date of Patent: March 19, 2019Assignee: LYTIX BIOPHARMA ASInventors: John S. Svendsen, Wenche Stensen, Frederick A. Leeson
-
Patent number: 10231955Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: GrantFiled: February 12, 2015Date of Patent: March 19, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert O. Williams, III, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
-
Patent number: 10231956Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: August 3, 2016Date of Patent: March 19, 2019Assignee: Samumed, LLCInventors: Sunil Kumar Kc, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, John Hood
-
Patent number: 10231957Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.Type: GrantFiled: June 1, 2018Date of Patent: March 19, 2019Assignee: CELGENE QUANTICEL RESEARCH, INC.Inventors: Young K. Chen, Michael Brennan Wallace
-
Patent number: 10231958Abstract: Embodiments of the invention are directed to methods and compositions using low dose sorafenib to enhance a cancer therapy.Type: GrantFiled: October 23, 2015Date of Patent: March 19, 2019Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: Alexander James Roy Bishop
-
Patent number: 10231959Abstract: Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.Type: GrantFiled: December 8, 2016Date of Patent: March 19, 2019Inventor: Louis Habash
-
Patent number: 10231960Abstract: The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.Type: GrantFiled: August 26, 2016Date of Patent: March 19, 2019Assignee: KemPharm Inc.Inventors: Sven Guenther, Guochen Chi, Bindu Bera, Travis Mickle, Sanjib Bera
-
Patent number: 10231961Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.Type: GrantFiled: February 15, 2017Date of Patent: March 19, 2019Assignee: GENUS LIFESCIENCES INC.Inventors: Jeffrey M. Moshal, Michael Libman
-
Patent number: 10231962Abstract: The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.Type: GrantFiled: December 4, 2014Date of Patent: March 19, 2019Assignee: Nalpropion Pharmaceuticals, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 10231963Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.Type: GrantFiled: April 17, 2017Date of Patent: March 19, 2019Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
-
Patent number: 10231964Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: October 5, 2017Date of Patent: March 19, 2019Assignee: Nalpropion Pharmaceuticals, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 10231965Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.Type: GrantFiled: February 17, 2015Date of Patent: March 19, 2019Assignees: IGNYTA, INC., NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Jonathan Lim, Elena Ardini, Maria Menichincheri
-
Patent number: 10231966Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.Type: GrantFiled: October 27, 2017Date of Patent: March 19, 2019Assignee: Pulmokine, Inc.Inventor: Lawrence S. Zisman
-
Patent number: 10231967Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: January 31, 2018Date of Patent: March 19, 2019Assignee: AstraZeneca ABInventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 10231968Abstract: The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure.Type: GrantFiled: August 1, 2016Date of Patent: March 19, 2019Inventors: David R. Hardten, Richard L. Lindstrom
-
Patent number: 10231969Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.Type: GrantFiled: March 13, 2017Date of Patent: March 19, 2019Assignee: GI Therapeutics, Inc.Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
-
Patent number: 10231970Abstract: A method of synthesizing a heteropolycycle, the method involving: reacting a bisepoxide with a first heteroatom nucleophile, to obtain a mixture comprising a diol compound; and further processing, to obtain the heteropolycycle with at least two heteroatoms within its polycyclic backbone, wherein each nitrogen within the polycyclic backbone of the heteropolycycle is introduced into the polycyclic backbone via an amine nucleophile.Type: GrantFiled: September 30, 2015Date of Patent: March 19, 2019Assignee: NV HeterocyclesInventor: Derek Alton Lightner
-
Patent number: 10231971Abstract: The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.Type: GrantFiled: June 22, 2016Date of Patent: March 19, 2019Assignee: AVIXGEN INC.Inventor: Mi Jeong Kim
-
Patent number: 10231972Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with 4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide.Type: GrantFiled: November 12, 2015Date of Patent: March 19, 2019Assignee: MERCK PATENT GMBHInventors: Friedhelm Bladt, Manja Friese-Hamim
-
Patent number: 10231973Abstract: The present application relates to maleates of a compound of Formula I, methods for preparing the same, pharmaceutical compositions thereof and uses thereof in the treatment of tumors, such as non-small cell lung cancer, breast cancer, and other malignant tumors.Type: GrantFiled: March 18, 2016Date of Patent: March 19, 2019Assignees: Chai Tai Tianqing Pharmaceutical Group Co., Ltd., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Xiquan Zhang, Song Tang, Weiwei Feng, Xin Tian, Zhilin Chen, Hongmei Gu, Hongjiang Xu, Fei Liu
-
Patent number: 10231974Abstract: The present invention relates to pharmaceutical compositions containing a combination of reduced forms of folate, liver protectors, vitamins, and essential or non-essential amino acids, useful in preventing the adverse effects associated with prolonged use of dihydrofolate reductase inhibitors.Type: GrantFiled: May 4, 2016Date of Patent: March 19, 2019Assignee: Companion Therapeutics, LLCInventors: Julio César Villamil Torres, Camilo Rey Ferro
-
Patent number: 10231975Abstract: Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.Type: GrantFiled: June 14, 2017Date of Patent: March 19, 2019Assignee: Horizon Orphan LLCInventors: Jeffery S. Loutit, Elizabeth E. Morgan, Michael N. Dudley, David C. Griffith, Olga Lomovskaya
-
Patent number: 10231976Abstract: Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids.Type: GrantFiled: February 7, 2011Date of Patent: March 19, 2019Assignee: PRAIRIE PHARMACEUTICALS LLCInventor: Tao Tom Du
-
Patent number: 10231977Abstract: Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel and ethinyl estradiol, comprising an acrylic polymer matrix. Methods of making and using such systems also are described.Type: GrantFiled: March 14, 2016Date of Patent: March 19, 2019Assignee: NOVEN PHARMACEUTICALS, INC.Inventors: Prashant Patel, Viet Nguyen, Jun Liao
-
Patent number: 10231978Abstract: The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one other agent selected from the group consisting of tamoxifen, raloxifene or functional equivalent thereof, and an aromatase inhibitor.Type: GrantFiled: April 30, 2015Date of Patent: March 19, 2019Assignees: SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH, CHANGZHOU RUIMING PHARMACEUTICAL COMPANY, LTD.Inventors: Jun Yang, Huijuan Shi, Wenping Xu
-
Patent number: 10231979Abstract: Methods for modulating inflammation using progesterone metabolites are disclosed. More particularly, methods of administering progesterone metabolites, 6?-hydroxyprogesterone (6?-OHP) and 16?-hydroxyprogesterone (16?-OHP) are disclosed for mitigating inflammation in various tissue types in the body.Type: GrantFiled: August 5, 2016Date of Patent: March 19, 2019Assignee: Indiana University Research and Technology CorporationInventor: Avinash Shivaputrappa Patil
-
Patent number: 10231980Abstract: The present invention provides certain cortexolone derivatives of formula (I), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.Type: GrantFiled: October 7, 2015Date of Patent: March 19, 2019Assignee: COSMO TECHNOLOGIES LTD.Inventor: Mara Gerloni
-
Patent number: 10231981Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: August 3, 2017Date of Patent: March 19, 2019Assignees: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.Inventors: Xiaoping Zhang, Kimio Terao, Olivier Alfred Harari
-
Patent number: 10231982Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.Type: GrantFiled: July 31, 2018Date of Patent: March 19, 2019Assignee: Pop Test Oncology Limited Liability CompanyInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Patent number: 10231983Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.Type: GrantFiled: August 22, 2018Date of Patent: March 19, 2019Assignee: Corcept Therapeutics, Inc.Inventor: Andreas Moraitis
-
Patent number: 10231984Abstract: The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.Type: GrantFiled: May 4, 2017Date of Patent: March 19, 2019Assignee: Nektar TherapeuticsInventors: Timothy A. Riley, Lin Cheng
-
Patent number: 10231985Abstract: The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.Type: GrantFiled: October 8, 2014Date of Patent: March 19, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE POITIERS, UNIVERSITY OF EXETERInventors: Miroslava Spanova, Thierry Ferreira, Romain Clement, Shalinee Dhayal, Noël Morgan
-
Patent number: 10231986Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: GrantFiled: September 25, 2015Date of Patent: March 19, 2019Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-François Griffon, Guillaume Brandt, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistar James Stewart
-
Patent number: 10231987Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.Type: GrantFiled: March 3, 2014Date of Patent: March 19, 2019Assignee: Chiesi Farmaceutici S.p.A.Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
-
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
Patent number: 10231988Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.Type: GrantFiled: August 7, 2017Date of Patent: March 19, 2019Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Kevin Fitzgerald, Gregory Hinkle -
Patent number: 10231989Abstract: Provided are a novel renal failure progression inhibitor, prophylactic agent for renal failure, and indoxyl sulfate production inhibitor, intended for human use, in particular, for a patient with renal failure. The renal failure progression inhibitor, prophylactic agent for renal failure, and indoxyl sulfate production inhibitor each comprises paramylon derived from Euglena or a processed product thereof as an active ingredient. In the case of the renal failure progression inhibitor, for example, paramylon is continuously orally administered to a patient suffering from chronic renal failure, undergoing a dialysis therapy, several times per day in a dose of 1 to 5 g per intake. In particular, the renal failure progression inhibitor is singly administered to the patient in a capsule or powdered preparation at a prescribed time interval before and after administration of other drugs.Type: GrantFiled: September 29, 2015Date of Patent: March 19, 2019Assignee: Euglena Co., Ltd.Inventors: Ayaka Nakashima, Yuta Asayama, Osamu Iwata, Kengo Suzuki
-
Patent number: 10231990Abstract: The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof.Type: GrantFiled: July 28, 2011Date of Patent: March 19, 2019Assignee: Horus PharmaInventors: Claude Claret, Martine Claret, Carole Gard
-
Patent number: 10231991Abstract: The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides and extracellular matrix binding (ECM) peptides that are tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA and to tissues such as cartilage. The novel biomaterial compositions can be used to coat or chemically modify cartilage or tissues with a biologically compatible polymer having HA binding peptides, which allow HA to bind to the surface of the cartilage or tissues. Methods of using same are also provided.Type: GrantFiled: July 16, 2014Date of Patent: March 19, 2019Assignee: The Johns Hopkins UniversityInventors: Anirudha Singh, Shimon Unterman, Michael Corvelli, Jennifer Elisseeff
-
Patent number: 10231992Abstract: The present invention relates to an antioxidant composition comprising a combination of galatomannan and N-acetyl cysteine for its use in the treatment of a skin disease or condition resulting from reactive oxygen species production in the skin or involving reactive oxygen species production in the skin, to a hydrogel containing said combination as well as to dressing wounds comprising said hydrogel and its use in the healing of ulcers, wounds, burns and scalds.Type: GrantFiled: October 3, 2016Date of Patent: March 19, 2019Assignee: HISTOCELL, S.L.Inventors: María Begoña Castro Feo, Iker Azcoitia Ramsden, Teodoro Palomares Casado, Jone Herrero De Miguel, Ana Isabel Alonso Varona, Maite Del Olmo Basterrechea
-
Patent number: 10231993Abstract: A biocompatible polymer to which a plurality of clot-modulating peptides (CMPs) are bound. The polymer comprises repeating units of hydrophilic monomers and display monomers to which the CMPs are bound. For example, the CMPs can be fibrin binding peptides (FBPs) that enhance clot formation by cross-linking that occurs within and between fibers by the plurality of fibrin-binding peptides during fibrin polymerization. The polymers of the invention can be used to modulate clotting in a variety of ways via multivalent display of fibrin-binding peptides and other clot-binding and clot-modulating moieties on polymer or co-polymer backbones. In addition to clot-modulating moieties, imaging agents and therapeutic agents can be conjugated to the polymers to facilitate imaging of blood flow and thrombosis, and for treatment of clotting-related disorders.Type: GrantFiled: June 27, 2014Date of Patent: March 19, 2019Assignee: University of Washington through its Center for CommercializationInventors: Suzie H. Pun, Leslie Chan, Nathan J. White
-
Patent number: 10231994Abstract: The use of selenite- or selenate-containing preparations supplemented with pharmaceutically acceptable or food-compatible acids for the preparation of an agent intended for topical or buccal application or mucosal administration is described.Type: GrantFiled: October 5, 2017Date of Patent: March 19, 2019Assignee: SELO MEDICAL GMBHInventors: Bodo Kuklinski, Peter Kössler, Norbert Fuchs
-
Patent number: 10231995Abstract: The use of selenite- or selenate-containing preparations supplemented with pharmaceutically acceptable or food-compatible acids for the preparation of an agent intended for topical or buccal application or mucosal administration is described.Type: GrantFiled: October 5, 2017Date of Patent: March 19, 2019Assignee: SELO MEDICAL GMBHInventors: Bodo Kuklinski, Peter Kössler, Norbert Fuchs
-
Patent number: 10231996Abstract: The present invention relates to highly biocompatible or nontoxic PVP (poly(n-vinyl-2-pyrrolidone) coated silver prussian blue nanoparticles (SPB-NPS: Ag3[Fe(CN)6] where PVP acts as stabilizing or capping agent. The as-synthesized nanoparticles (SPB-NPs) have been thoroughly characterized by several analytical tools. The SPB-NPs are highly stable for more than two weeks towards different physiological buffers or solutions with different pH (pH=6, ?7.4 & ?8). These nanoparticles (SPB-NPs) exhibit biocompatibility towards various normal cells (HUVEC, CHO, & ECV304) but show significant inhibition of proliferation of different cancer cells in vitro and tumor growth in C57/BL6/J mice model (aggressive murine melanoma cancer model: B16F10). Additionally, the SPB-NPs show excellent antibacterial activity towards gram-negative (E. coli) and gram-positive (B. subtilis) bacteria.Type: GrantFiled: February 22, 2016Date of Patent: March 19, 2019Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Sudip Mukherjee, Chitta Ranjan Patra
-
Patent number: 10231997Abstract: Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions.Type: GrantFiled: August 15, 2013Date of Patent: March 19, 2019Assignee: The University of ChicagoInventors: Kae M. Pusic, Yelena Y. Grinberg, Richard P. Kraig, Aya D. Pusic
-
Patent number: 10231998Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.Type: GrantFiled: June 16, 2017Date of Patent: March 19, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
-
Patent number: 10231999Abstract: The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.Type: GrantFiled: August 13, 2015Date of Patent: March 19, 2019Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Sang Chul Lee, Baek Soo Han, Kwang-Hee Bae, Hyejin Kim, Won Kon Kim, Kyoung Jin Oh